Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrike Schatz

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Herz|April 2, 2025
Obesity and heart failure-the role of GLP-1 receptor agonistsGregor Simonis, Ulrike Schatz
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|July 14, 2022
COVID-19 and Lipid DisordersUlrich Julius, Ulrike Schatz, Sergey Tselmin, et al.
Deutsche Medizinische Wochenschrift (1946)|December 6, 2021
[State of the Art: Statin Therapy]Ulrich Laufs, Oliver Weingärtner, Ursula Kassner, et al.
Deutsche Medizinische Wochenschrift (1946)|April 19, 2023
[Correction: State of the art: lipoprotein apheresis]Ulrike Schatz, Volker J J Schettler, Ulrich Julius
Deutsche Medizinische Wochenschrift (1946)|March 29, 2023
[State of the art: lipoprotein apheresis]Ulrike Schatz, Volker J J Schettler, Ulrich Julius
Global Cardiology Science & Practice|November 22, 2021
Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factorTina Z Khan, Ulrike Schatz, Stefan R Bornstein, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|April 5, 2013
Why an apheresis center should offer more than one lipoprotein apheresis methodUlrich Julius, Sabine Fischer, Ulrike Schatz, et al.
Atherosclerosis. Supplements|December 11, 2019
Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresisSergey Tselmin, Ulrich Julius, Nadine Weinert, et al.
Journal of Cardiovascular Development and Disease|July 26, 2020
Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?Ulrich Julius, Solveig Kuss, Sergey Tselmin, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 30, 2022
The development of lipoprotein apheresis in Saxony in the last yearsSolveig Frieda Rosa Kuss, Ulrike Schatz, Sergey Tselmin, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Herz|April 2, 2025
Obesity and heart failure-the role of GLP-1 receptor agonistsGregor Simonis, Ulrike Schatz
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|July 14, 2022
COVID-19 and Lipid DisordersUlrich Julius, Ulrike Schatz, Sergey Tselmin, et al.
Deutsche Medizinische Wochenschrift (1946)|December 6, 2021
[State of the Art: Statin Therapy]Ulrich Laufs, Oliver Weingärtner, Ursula Kassner, et al.
Deutsche Medizinische Wochenschrift (1946)|April 19, 2023
[Correction: State of the art: lipoprotein apheresis]Ulrike Schatz, Volker J J Schettler, Ulrich Julius
Deutsche Medizinische Wochenschrift (1946)|March 29, 2023
[State of the art: lipoprotein apheresis]Ulrike Schatz, Volker J J Schettler, Ulrich Julius
Global Cardiology Science & Practice|November 22, 2021
Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factorTina Z Khan, Ulrike Schatz, Stefan R Bornstein, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|April 5, 2013
Why an apheresis center should offer more than one lipoprotein apheresis methodUlrich Julius, Sabine Fischer, Ulrike Schatz, et al.
Atherosclerosis. Supplements|December 11, 2019
Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresisSergey Tselmin, Ulrich Julius, Nadine Weinert, et al.
Journal of Cardiovascular Development and Disease|July 26, 2020
Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?Ulrich Julius, Solveig Kuss, Sergey Tselmin, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 30, 2022
The development of lipoprotein apheresis in Saxony in the last yearsSolveig Frieda Rosa Kuss, Ulrike Schatz, Sergey Tselmin, et al.
Pageof 3